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graphic measures predict left ventricular (LV) reverse remodeling
and clinical outcome in patients receiving cardiac resynchronization
therapy (CRT).
OBJECTIVES The objectives of this study were to compare predic-
tive abilities of different vectorcardiographic measures (QRS area
and sum absolute QRS-T integral) and transformation methods
(Kors and inverse Dower) and to assess the independent association
between the best predictor and outcomes in CRT recipients.
METHODS This retrospective study included CRT recipients with a
digital baseline electrocardiogram, QRS duration 120 ms, and
ejection fraction 35%. The end point was a composite of heart
transplantation, LV assist device implantation, or all-cause death.
Analyses were performed for the overall cohort and for a prespeci-
ﬁed subgroup of patients with left bundle branch block (LBBB).
RESULTS Of 705 included patients with a mean age of 66.66 11.5
years, 492 (70%) were men, 374 (53%) had ischemic heart disease,
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In multivariable Cox regression, patients with a smaller QRS area
( 95 mVs) had an increased hazard in the overall cohort (adjusted
hazard ratio 1.65; 95% CI 1.25-2.18 P, .001) and in the LBBB sub-
group (adjusted hazard ratio 1.95; 95% CI 1.38-2.76 P, .001). QRS
area was associated with outcome in patients with QRS duration
,150 ms (unadjusted hazard ratio 3.85; 95% CI 2.02-7.37
P , .001) and in patients with QRS duration 150 ms (unadjusted
hazard ratio 1.76; 95% CI 1.32-2.34 P , .001).
CONCLUSION Vectorcardiographic QRS area is associated with sur-
vival free from heart transplantation and LV assist device implanta-
tion in CRT recipients.
KEYWORDS Cardiac resynchronization therapy; Heart failure; Left
bundle branch block; QRS area; QRS duration; Sum absolute QRS-T
integral; Vectorcardiography
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Although cardiac resynchronization therapy (CRT) has been an
established treatment for patients with prolonged QRS durationand heart failure for several years,1–3 a substantial proportion of
patients do not beneﬁt from the treatment.4,5 In current
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different vectorcardiographic measures of dyssynchrony have
been proposed, namely, QRS area and sum absolute QRS-T in-
tegral (SAI QRS-T), and these have been shown to identify
delayed activation of the left ventricular (LV) lateral wall, pre-
dict echocardiographic response to CRT, and, in a small retro-
spective cohort study, predict survival after CRT.7–10
Currently, there are no published comparisons of these 2
vectorcardiographic measures or the different matrices (the
Kors matrix and the inverse Dower matrix) used for the
derivation of the vectorcardiogram from the digital 12-lead elec-
trocardiogram (ECG).11,12
The objectives of this study were to compare the predic-
tive abilities of the 2 different vectorcardiographic measures
and the 2 transformation matrices and to assess the associa-
tion between the best predictor and long-term outcome in
CRT recipients.Methods
This was a retrospective cohort study performed at Duke Uni-
versity Medical Center. The study was approved by the Duke
Health Institutional Review Board and complies with the
Declaration of Helsinki.Study population
All patients who received CRT with deﬁbrillator from April
1, 2006 to September 30, 2015 were identiﬁed using an insti-
tutional data set prepared for the National Cardiovascular
Data Registry. We included patients who received a de
novo CRT owing to symptomatic heart failure with LV ejec-
tion fraction 35% and had an ECG available with QRS
duration120 ms within 180 days before CRT implantation.x y
x y
QRS areaQRS areax = 71 µVs
SAI QRS-TSAI QRS-Tx = 127 µVs
QRS area = (QRS areax2 + QRS ar
SAI QRS-T = SAI QRS-Tx + SAI QR
A
B
Figure 1 Examples of calculation of QRS area and SAI QRS-T from the vectorcard
baseline from the onset to the offset of theQRS complex.B: SAIQRS-T is calculated a
wave deﬂections. The vertical lines mark the onsets and offsets of the QRS complexPatients were excluded if the LV lead could not be implanted,
the patient demonstrated second- or third-degree atrioventric-
ular block, or the patient had missing follow-up data.Electro- and vectorcardiographic analyses
TheECGmost proximal toCRT implantationwas reanalyzed in
theMUSECardiology Information System version 8.0.2.10132
with 12SL analysis software version 241 (GE Healthcare, Mil-
waukee, WI) and exported in Extensible Markup Language
(XML) format. QRS morphology was designated by 2 readers
(D.J.F. and K.E.) blinded to outcome. Left bundle branch block
(LBBB)morphologywas further divided into strict andnonstrict
LBBB using the criteria described by Strauss et al.13 QRS onset
and offset and thereby QRS duration as detected using 12SL
software were veriﬁed or manually corrected if needed.
Vectorcardiogramswere derived from theXML ﬁles using
customized MATLAB software (MathWorks, Inc., Natick,
MA) using both the inverse Dower and Kors matrices.11,12
Using the median beat, QRS area and SAI QRS-Twere calcu-
lated as described previously by others.8,9 QRS area was
calculated as (QRSx
2 1 QRSy
2 1 QRSz
2)1/2, with QRSx/y/z
being the integral between the ventricular deﬂection and the
baseline from the onset to the offset of the QRS complex in
the x, y, and z leads, respectively (Figure 1A). SAI QRS-T
was calculated as the sum of the absolute areas between the
deﬂection and the baseline of the entire QRS-T waveform
from the x, y, and z leads (Figure 1B). Thus, a total of 4
vectorcardiographic measures were derived:
1. QRS area (Kors)
2. QRS area (inverse Dower)
3. SAI QRS-T (Kors)
4. SAI QRS-T (inverse Dower)z
z
y = -6 µVs QRS areaz = 94 µVs
y = 58 µVs SAI QRS-Tz = 170 µVs
eay2 + QRS areaz2)½ = 118 µVs
S-Ty + SAI QRS-Tz = 355 µVs
iogram.A:QRS area is calculated using the integral between the deﬂection and
s the sum of the orthogonal leads’ absolute area under the QRS complex and T-
and the T-wave offset. SAI QRS-T 5 sum absolute QRS-T integral.
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The study end point was a composite of heart transplantation,
LV assist device implantation, or all-cause death. End point
ascertainment was performed on May 24, 2017, via a query
of the Duke Enterprise Data Uniﬁed Content Explorer by
incorporating data from billing claims, hospital records,
and the Social Security Death Index.14Statistical analyses
Continuous normally distributed variables are reported as
mean 6 SD and differences were tested using the Student t
test, while nonnormally distributed variables are reported as
median (25th–75th percentile) and differences were tested
using the Wilcoxon rank-sum test. Categorical variables
were compared using the Fisher exact test.
Time-dependent receiver operating characteristic (ROC)
curves were created to assess the ability of the 4 vectorcardio-
graphic measures to predict the occurrence of the study end
point and the vectorcardiographic measurement with the
largest area under the curve (AUC) at 3 years after CRT
implantation was used for all subsequent analyses. The
median value for the overall cohort was used to separate co-
horts into 2 groups.
Kaplan-Meier plots were used to depict the cumulative
hazard of the composite outcome and differences wereTable 1 Baseline characteristics of the overall cohort
Characteristic All (N 5 705) QRS area 95
Days from ECG to CRT* 6 (1–23) 7 (1–24)
Age (y) 66.6 6 11.5 66.4 6 10.9
Male sex 492 (70) 270 (76)
Ischemic heart disease 374 (53) 216 (61)
LVEF (%) 24 6 7 24 6 7
NYHA class III/IV 584 (83) 309 (88)
QRS duration (ms) 163 6 27 153 6 25
QRS duration ,150 ms 239 (34) 186 (53)
QRS morphology
Strict LBBB 358 (51) 120 (34)
Nonstrict LBBB 107 (15) 85 (24)
RV paced 119 (17) 38 (11)
RBBB 27 (4) 26 (7)
RBBB 1 LAFB 49 (7) 44 (12)
RBBB 1 LPFB 5 (1) 5 (1)
Nonspeciﬁc IVCD 40 (6) 35 (10)
PR interval (ms) 186 6 40 193 6 44
First-degree AV block 118 (17) 78 (22)
Atrial ﬁbrillation/ﬂutter 243 (34) 127 (36)
Hypertension 513 (73) 259 (73)
Diabetes 266 (38) 144 (41)
Cerebrovascular disease 89 (13) 51 (14)
Chronic lung disease 151 (21) 83 (24)
Creatinine level (mg/dL)* 1.2 (1.0–1.6) 1.3 (1.0–1.6)
Creatinine level .1.2 mg/dL 323 (46) 186 (53)
ACE inhibitor/ARB 540 (77) 260 (74)
b-Blocker 627 (90) 300 (86)
Diuretics 583 (84) 295 (85)
Data are presented as mean 6 SD or as n (%).
ACE5 angiotensin-converting enzyme; ARB5 angiotensin II receptor blocker;
trocardiogram; IVCD5 unspeciﬁc intraventricular conduction delay; LAFB5 left ant
fascicular block; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Hear
*Values are presented as median (25th–75th percentile), and the Wilcoxon rank-sassessed using log-rank statistics. Cox proportional hazard
models were used for assessing univariable and multivariable
predictors of the composite outcome. Multivariable models
were adjusted for ischemic heart disease, QRS morphology,
QRS duration,150 ms, atrial ﬁbrillation/ﬂutter, and univari-
able predictors with a P value of ,.10. Proportional hazards
assumptions were veriﬁed graphically using plots of Schoen-
feld residuals. Sensitivity analysis with stepwise removal of
the covariates in the model was performed. Analyses were
performed for the overall cohort and for the prespeciﬁed sub-
groups of patients with LBBB and non-LBBB QRS
morphologies.
All statistical analyses were performed in RStudio
version 1.1.423 (RStudio, Inc, Boston, MA) running R
version 3.3.2 (R Foundation for Statistical Computing,
Vienna, Austria). The R packages “survival”15 and “time-
ROC”16 were used for survival analyses and time-
dependent ROC curves. A 2-sided P value of ,.05 was
considered statistically signiﬁcant.Results
A total of 1001 patients underwent CRT implantation at Duke
University Medical Center during the study period. After
excluding patients with a missing baseline digital ECG (n 5
159, 16%), prior LV lead (n 5 12, 1%), QRS durationmVs (n 5 353) QRS area .95 mVs (n 5 352) P
5 (1–22) .22
66.7 6 12.2 .76
222 (63) ,.001
158 (45) ,.001
24 6 7 .69
275 (78) .001
174 6 26 ,.001
53 (15) ,.001
238 (68) ,.001
22 (6) ,.001
81 (23) ,.001
1 (,1) ,.001
5 (1) ,.001
0 .06
5 (1) ,.001
179 6 34 ,.001
40 (11) ,.001
116 (33) .43
254 (72) .74
122 (35) .10
38 (11) .17
68 (19) .20
1.1 (0.9–1.4) ,.001
137 (39) ,.001
280 (80) .10
327 (93) .002
288 (82) .41
AV5 atrioventricular; CRT5 cardiac resynchronization therapy; ECG5 elec-
erior fascicular block; LBBB5 left bundle branch block; LPFB5 left posterior
t Association; RBBB 5 right bundle branch block; RV 5 right ventricular.
um test was used for statistical testing.
Figure 2 Kaplan-Meier plot of event-free survival for the overall cohort. The
curves are in relation to QRS area above (blue) or below (red) the median value
95mVs.The hazard ratio is unadjusted.CI5 conﬁdence interval;CRT5 cardiac
resynchronization therapy; LVAD5 implantable left ventricular assist device.
216 Heart Rhythm, Vol 16, No 2, February 2019,120 ms (n5 56, 6%), LV ejection fraction.35% (n5 17,
2%) or missing (n5 7,,1%), failed LV lead (n5 8,,1%),
second- or third-degree atrioventricular block (n5 34, 3%), or
missing follow-up data (n 5 3, ,1%), a total of 705 patients
remained. Of the included patients, 492 (70%) were men, the
mean age was 66.6 6 11.5 years, 374 (53%) had ischemic
heart disease, 465 (66%) had LBBB, and the mean QRS dura-
tion was 163 6 27 ms (Table 1).
Predictive ability of vectorcardiographic
measurements
The Kors-derived QRS area predicted the probability of
reaching the study end point 3 years after CRT implantation
better than did the inverse Dower-derived QRS area (AUC
0.645 vs 0.620; P5 .005), and SAI QRS-T derived by either
the Kors method (AUC 0.645 vs 0.625; P 5 .03) or the
inverse Dower method (AUC 0.645 vs 0.608; P 5 .001)
(Supplemental Figure 1). Based on these results, the Kors-
derived QRS area was used for all subsequent analyses.
Patient characteristics by QRS area
The median (25th–75th percentile) QRS area derived by
the Kors method for the overall cohort was 95 mVs
(63–127 mVs). Patients with QRS area 95 mVs were more
often men with ischemic heart disease, more advanced
New York Heart Association functional class, longer PR in-
terval, shorter QRS duration, higher serum creatinine level,
and were less likely to receive b-blocker medication. Patients
with QRS area .95 mVs were more likely to have strict
LBBB or have right ventricular pacing, whereas all other
QRS morphologies were more common in patients with
QRS area 95 mVs (Table 1).
Follow-up
Over a median follow-up of 3.1 years (25th–75th percentile
1.8–5.4 years), 312 patients (44%) reached the study endpoint. The most common reason for reaching the end point
was death (n5 263 [37%]) followed by LV assist device im-
plantation (n 5 26 [4%]) and heart transplantation (n 5 23
[3%]). During follow-up, 194 patients with QRS area 95
mVs (55%) experienced an end point as compared with 118
patients with QRS area .95 mVs (34%) (Figure 2). QRS
area was associated with the likelihood of reaching the study
end point in both univariable (unadjusted hazard ratio 2.11;
95% conﬁdence interval [CI] 1.68–2.65; P, .001) andmulti-
variable analyses adjusting for QRS duration and
morphology, age, sex, ischemic heart disease, ﬁrst-degree
atrioventricular block, atrial ﬁbrillation/ﬂutter, LV ejection
fraction, New York Heart Association functional class, creat-
inine level, cerebrovascular disease, chronic lung disease,
angiotensin-converting enzyme inhibitor or angiotensin II re-
ceptor blocker use, and b-blocker use (adjusted hazard ratio
1.65; 95% CI 1.25–2.18; P , .001) (Table 2).QRS area and outcomes in LBBB and non-LBBB
subgroups
The median QRS area for the LBBB subgroup was 101 mVs,
while it was 77 mVs for the non-LBBB subgroup
(P , .001). In the LBBB subgroup, 260 of 465 patients
(56%) had QRS area .95 mVs. The baseline characteristics
for the LBBB subgroup are described in Supplemental
Table 1. Among patients with QRS area 95 mVs, 109
(53%) reached the composite end point as compared with 77
patients withQRS area.95 mVs (30%) (unadjusted hazard ra-
tio 2.35; 95% CI 1.75–3.15; P , .001) (Figure 3A). In the
adjusted model including the same covariates as the model
for the overall cohort, QRS area remained signiﬁcantly associ-
ated with the composite outcome (adjusted hazard ratio 1.95;
95% CI 1.38–2.76; P , .001) in patients with LBBB.
Among patients without LBBB, QRS area .95 mVs was
much more common in patients with right ventricular pacing
(81 of 119 [68%]) than all other non-LBBB QRS morphol-
ogies (11 of 121 [9%]). QRS area 95 mVs was associated
with the study outcome in univariable analysis (unadjusted
hazard ratio 1.55; 95% CI 1.07–2.25; P 5 .02) (Figure 3B).
After adjusting for QRS duration and morphology, age, sex,
ischemic heart disease, and atrial ﬁbrillation/ﬂutter, QRS
area was not signiﬁcantly associated with the study end point
(adjusted hazard ratio 1.50; 95% CI 0.94–2.39; P 5 .09) in
patients without LBBB. Among patients without non-
LBBB and without right ventricular pacing, QRS area
95 mVs demonstrated a nonsigniﬁcant association with
worsened outcomes (unadjusted hazard ratio 2.76; 95% CI
0.86–8.80; P 5 .09).Outcome in relation to QRS area in combination
with QRS duration
In patients with QRS duration,150 ms, 53 of 239 (22%) had
QRS area.95 mVs. In patients with QRS duration150 ms,
167 of 466 (36%) had QRS area95 mVs. In the LBBB sub-
group, 51 of 185 patients with QRS duration,150 ms (28%)
had QRS area .95 mVs and 71 of 280 patients with QRS
Table 2 Association of QRS area and baseline variables to outcome in univariable and multivariable analyses for the overall cohort
Variable
Univariable Cox regression Multivariable Cox regression
HR 95% CI P HR 95% CI P
Age (per 5-y increase) 1.05 1.00–1.10 .05 0.98 0.93–1.04 .54
Male sex 1.61 1.23–2.11 ,.001 1.00 0.73–1.36 .99
Ischemic heart disease 1.69 1.34–2.12 ,.001 1.35 1.04–1.75 .03
QRS duration ,150 ms 1.44 1.14–1.81 .002 1.27 0.91–1.77 .15
QRS morphology
Strict LBBB (1.00) (1.00)
Nonstrict LBBB 1.66 1.22–2.27 .001 0.87 0.58–1.31 .51
RV paced 1.49 1.10–2.02 .01 1.17 0.82–1.67 .38
Nonspeciﬁc IVCD 2.04 1.33–3.14 .001 1.06 0.65–1.72 .83
RBBB 1 LAFB 1.31 0.83–2.06 .24 0.49 0.30–0.80 .005
RBBB 1 LPFB 19.97 7.91–50.39 ,.001 6.96 2.66–18.20 ,.001
RBBB 2.01 1.13–3.56 .02 1.19 0.64–2.22 .59
First-degree AV block 1.63 1.24–2.13 ,.001 1.79 1.33–2.41 ,.001
Atrial ﬁbrillation/ﬂutter 2.00 1.59–2.50 ,.001 1.64 1.28–2.12 ,.001
LVEF (per 5% increase) 0.91 0.84–0.99 .03 0.91 0.83–1.00 .05
Hypertension 1.13 0.87–1.45 .36
Diabetes 1.18 0.94–1.48 .15
NYHA class III/IV 1.90 1.28–2.82 .001 1.49 0.99–2.26 .06
Creatinine level .1.2 mg/dL 2.39 1.90–3.00 ,.001 1.86 1.44–2.40 ,.001
Cerebrovascular disease 1.50 1.11–2.02 .009 1.23 0.90–1.70 .19
Chronic lung disease 1.72 1.35–2.20 ,.001 1.39 1.07–1.80 .01
ACE inhibitor/ARB 0.44 0.34–0.56 ,.001 0.57 0.44–0.74 ,.001
b-Blocker 0.57 0.41–0.78 ,.001 0.78 0.56–1.10 .16
Diuretics 1.23 0.87–1.74 .24
QRS area 95 mVs 2.11 1.68–2.65 ,.001 1.65 1.25–2.18 ,.001
ACE 5 angiotensin-converting enzyme; ARB 5 angiotensin II receptor blocker; AV 5 atrioventricular; CI 5 conﬁdence interval; HR 5 hazard ratio;
IVCD 5 unspeciﬁc intraventricular conduction delay; LAFB 5 left anterior fascicular block; LBBB 5 left bundle branch block; LPFB 5 left posterior fascicular
block; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart Association; RBBB 5 right bundle branch block; RV 5 right ventricular.
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95 mVs was associated with the study end point in univari-
able analysis in both patients with QRS duration ,150 ms
(unadjusted hazard ratio 3.85; 95% CI 2.02–7.37; P ,
.001) (Figure 4A) and patients with QRS duration 150
ms (unadjusted hazard ratio 1.76; 95% CI 1.32–2.34; P ,
.001) (Figure 4B). Similar results were found in the LBBB
subgroup when stratifying by QRS duration below or above
150 ms (Supplemental Figure 2).Figure 3 Kaplan-Meier plots of event-free survival for the LBBB (A) and non-L
below (red) 95 mVs. The hazard ratios are unadjusted. CI 5 conﬁdence interval; C
LVAD 5 implantable left ventricular assist device.Discussion
First, this study found that a smaller baseline QRS area calcu-
lated from derived vectorcardiograms is associated with an
increased hazard of death, heart transplantation, or LV assist
device implantation after CRT independently of critical base-
line characteristics such as QRS duration and morphology.
Second, the study found that the Kors method is superior to
the inverse Dower method in the derivation of theBBB (B) subgroups. The curves are in relation to QRS area above (blue) or
RT5 cardiac resynchronization therapy; LBBB5 left bundle branch block;
Figure 4 Kaplan-Meier plots of event-free survival for QRS duration below (A) or above (B) 150 ms for the overall cohort. The curves are in relation to QRS
area above (blue) or below (red) 95 mVs. The hazard ratios are unadjusted. CI 5 conﬁdence interval; CRT 5 cardiac resynchronization therapy;
LVAD 5 implantable left ventricular assist device.
218 Heart Rhythm, Vol 16, No 2, February 2019vectorcardiogram for prediction of CRT outcome using QRS
area. Third, it found that among the 2 most widely studied
vectorcardiography-based measures of LV electrical delay,
QRS area is superior to SAI QRS-T in the prediction of
adverse outcomes after CRT implantation. Finally, the study
ﬁndings suggest that especially in patients with QRS duration
,150 ms (ie, patients without a current class I indication for
CRT), QRS area has important prognostic value.Vectorcardiographic measures as predictors of CRT
outcome
Vectorcardiography was developed in the 1950s but has been
seldom used clinically for the past 20 years. With the devel-
opment of digital ECG signal processing, renewed interest in
vectorcardiography has emerged, largely as a tool for patient
selection in CRT. The digital 12-lead ECG allows the digital
derivation of a vectorcardiogram that bears good resem-
blance and correlation with vectorcardiograms recorded
using Frank’s method.17,18 Prior studies have demonstrated
that QRS area identiﬁes delayed LV lateral wall activation
in CRT candidates, while SAI QRS-T correlates with a dys-
synchrony index determined by noninvasive ECG map-
ping.7,19 Thus, these measures were proposed to reﬂect LV
electrical dyssynchrony and thereby identify a substrate
amenable to CRT. Subsequent studies demonstrated that
QRS area and SAI QRS-T predicted LV reverse remodeling
and long-term outcome after CRT.8–10Current guidelines for the selection of CRT
candidates
Currently, QRS duration and morphology are the only ECG
measures incorporated in guidelines for the selection of CRT
candidates.6 The presence of LBBB and QRS duration150
ms are associated with a high likelihood of a positive
outcome after CRT implantation.20–23 However, this study
found that within this cohort of patients with a current class
I indication for CRT,6w25% have QRS area 95 mVs andan increased hazard of adverse outcome after CRT implanta-
tion. In addition, this study ﬁnds that QRS area is strongly
associated with long-term outcome in patients with QRS
duration ,150 ms both in the overall cohort and in the
LBBB subgroup, that is, patients without a current class I
indication for CRT.
Strict vs nonstrict LBBB was a predictor of outcomes in
unadjusted analyses; however, in adjusted models, strict vs
nonstrict LBBB was not a signiﬁcant predictor, in contrast
to QRS area, which remained a robust predictor of outcomes.
Taken together, these data suggest that QRS area is a more
powerful predictor of outcomes than is strict vs nonstrict
LBBB.
In patients without LBBB, a smaller QRS area was also
associated with an increased hazard of adverse outcome in
univariable analysis. However, the association was not sig-
niﬁcant in multivariable analysis, albeit the estimated hazard
ratio was not changed much (from 1.55 in univariable anal-
ysis to 1.50 in multivariable analysis). In patients without
LBBB or right ventricular pacing, ,10% had QRS area
.95 mVs. Nevertheless, there was a trend toward these
patients having a substantially better outcome than similar
patients with QRS area 95 mVs. As the LV has a signiﬁ-
cantly larger myocardial mass than does the right ventricle,
QRS area is mainly determined by electrical activation in
the LV and is thought to reﬂect LV dyssynchrony. The results
of this study suggest that an important minority of patients
with non-LBBB QRS morphology may have LV activation
delay, which might be amenable to correction using CRT.
However, owing to the lack of statistical power in these
exploratory analyses, further research is needed.
Study limitations
Themajor limitation of this study is the retrospective nature and
absence of a control group. To deﬁnitively establish that QRS
area effectively identiﬁes CRT candidates, studies that include
a control group of patients not receiving CRT are needed. Vec-
torcardiographymay simply identify patients with a high risk of
Emerek et al QRS Area Is Associated With Outcome After CRT 219adverse outcomes regardless of whether they beneﬁt fromCRT,
for example, by identifying patients with extensive myocardial
scarring. Neither this study nor the previously mentioned
studies8–10 included a control group who did not receive CRT,
and despite efforts to adjust for confounding, the risk of
residual confounding is inherent in the study design.
It is possible that the use of transformed 12-lead ECGs
rather than vectorcardiograms may have led to patient
misclassiﬁcation. However, a prior study has shown good
agreement between these methods,17 and furthermore,
12-lead ECGs (and not vectorcardiograms) are ubiquitous
in clinical practice.
Because of the relatively small study cohort, we were
unable to separately test and validate the QRS area threshold
in separate subpopulations. The ﬁndings should be replicated
in a prospective study to conﬁrm the predictive value of vec-
torcardiographic QRS area.
This study included only a clinical end point, and no data on
LV reverse remodeling or symptomatic improvement were
available. However, previous studies have shown that QRS
area is associatedwith LV reverse remodeling and acute hemo-
dynamic response toCRT.8,24 In addition, the single-center na-
ture of the study may decrease the generalizability of results.
Data on several device attributes and parameters were not
included in our adjusted models, including LV lead type and
position, percent biventricular pacing, and whether CRT
optimization was performed. Finally, since many patients un-
dergo CRT implantation at Duke University Medical Center
but have routine longitudinal care via referring providers,
comprehensive data on postimplantation device program-
ming and management were not available.Conclusion
Derived vectorcardiographic QRS area is independently
associated with survival free from heart transplantation and
LV assist device implantation regardless of QRS duration
and presence of LBBB. QRS area calculated from vectorcar-
diograms derived using the Kors method is superior to QRS
area derived using the inverse Dower method and to SAI
QRS-T from vectorcardiograms derived using either method.Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at https://doi.org/10.1016/j.hrthm.2018.
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